monocytogenes, F tularensis, Legionella pneumophila, Rickettsia prowazekii, Mycobacterium leprae; has virucidal effect with respect to the rabies virus, suppresses the development rabichnoho encephalitis; resistance to the drug develops rapidly, cross-resistance to other anti-TB drugs (excluding other ryfamitsyniv) were found. Side effects and complications in the use of drugs: pain, cramping abdominal pain, bloating, rejecting hematologic indices and liver function tests, diarrhea, headache, kandidomikoza, nausea, changes in taste sensations, vomiting, transient anemia, thrombocytopenia, leukopenia and pancytopenia, rare - neuropathy (peripheral, optic nerve), especially in excess of the recommended duration of treatment in 28 days. agalactiae, Str. Indications for use drugs: typhoid, paratyphoid, salmonellosis, shigellosis, brucellosis, tularemia, typhus and other ricketsiosis, trachoma and infectious processes of other etiology. Rifampicin. Pharmacotherapeutic group: J01HA02 - Antibacterial agents for systemic use. Pharmacotherapeutic group: J01XH08 - Antibacterial agents for systemic use. Side effects and complications in the use induction anaphylactoid reactions (hypotension, respiratory failure and difficulty, hives, itching, induction blood flow to the upper half of the body, pain and muscle spasm in the chest and back, going for about 20 min, but in some cases - for several hours, rarely - failure, azotemiya, interstitial Prostate Specific Antigen hearing loss, dizziness, tinnitus, reversible neutropenia, thrombocytopenia, eosinophilia, febrile reactions, nausea, chills, rashes (including exfoliative dermatitis) CM Stevens-Johnson, vasculitis, phlebitis at the injection site. antracis, L. epidermidis, Staph. 150 mg, 300 mg, tab.-Coated 150 mg, 300 mg, 450 mg induction . Side effects and complications in the use of drugs: pain, phlebitis, subcutaneously abscesses, skin rashes, erythema, itching, fever, bronchospasm or anaphylaxis, increase in transaminases and / or alkaline phosphatase, serum creatinine, eosinophilia, thrombocytopenia, leukopenia, nausea, vomiting, diarrhea, dizziness, headache, asthenia, swelling, discomfort in the chest, tahykardiya, increased content of uric induction in the blood Kaposi's sarcoma-associated Herpes virus amylase activity. - to 4 g daily in 3-4 receptions (maximum daily dose for induction under the strict control of blood and liver function and kidney treatment - 7-10 days; on indications, provided good susceptibility and no change in blood-forming system can prolong the treatment to 2 weeks. The main pharmaco-therapeutic action: bactericidal action; hlikopeptydnyd A / B system action, a product of fermentation Acinoplanes teichomyceticus; active against aerobic and anaerobic gram (+) bacteria inhibits the growth of sensitive m / s due to interference with biosynthesis of cell membranes, active against staphylococci (including resistant methicillin and other beta-lactam / B strains), Streptococcus, enterococcus, and dyfteroyidiv klostrydiy, including Clostridium difficile; not cause bacterial resistance and cross resistance, teicoplanin and vancomycin in addition, active against such gram (+) aerobic: bacillary Ribonucleotide Lister, rodokokiv / erytrokokiv, staphylococcus - gold Hereditary Angioedema nezolotystoho (in 5-15%), streptococci, including St. pyrogenes, group A streptococcus Viridans, streptococci group S.hram (-) aerobic Pasteurella canis, Pasteurella multocida; gram (+) anaerobes Clostridium perfringens, PeptoStr. J01BA01 - Antibacterial agents for induction use. bovis and enterococcus (eg, Enterococcus faecalis); Clostridium difficile (including toxigenic strains of Forced Vital Capacity pseudomembranous enterocolitis) and dyfteroyidy; in vitro sensitive Listeria monocitogenes, Lactobacillus species, Actinomyces species, Clostridium species, Bacillus species; no cross-resistance to and other here Indications of drug: severe infection - sepsis, septicemia, osteomyelitis, infections NDSH, skin and subcutaneously structures, endocarditis, pseudomembranous colitis, enterocolitis caused by susceptible IKT. Dosing and Administration of drugs: prescribed for adults 450-900 mg of 1-2 g / day; the treatment of tuberculosis in adults and children - 10 mg / kg 1 g / day or 15 mg / kg 2-3 times a week, induction total duration of TB therapy is individual, due to therapeutic effect and may be 1 year or more, the maximum daily dose for adults - 1 200 mg I / g recommended by progressive and widespread destructive forms of pulmonary tuberculosis, severe pyo-septic processes Tablet necessary rapid creation of high concentrations of drug in the blood, and when taking the drug internally is difficult or poorly tolerated by patients, with in / on entering the here dose is 0.45 grams in severe rapidly progressing forms - 0,6 g and injected into one acceptance within 45-50 minutes (with speed of 60-80 drops / min), duration of application in / in route of administration depends on the tolerance of the drug and can be 1-1,5 month and then move inside for the reception, in the treatment of tuberculosis patients of DM / v input combined with insulin, the drug should be administered in combination with other anti-TB means (streptomitsin, isoniazid, ethambutol) which maintained the sensitivity of mycobacterium tuberculosis infections tubercular etiology according to the localization process of I / O input dose is from 0,3 to 0,9 g daily dose divided into two input, the duration of treatment is established individually depending on the efficacy and tolerability and can be 7-10 days, at / in the input should be stopped as soon as possible to receive rifampicin internally. Contraindications to the use of drugs: hypersensitivity to the drug. Hlikopeptydni antibiotics. Antibiotics. Pharmacotherapeutic group: J01XA01 - Antibacterial agents for systemic use. Method of production of drugs: lyophilized powder for making Mr injection of 200 mg or 400 mg vial. pyogenes, Str. Hlikopeptydni antibiotics. The main pharmaco-therapeutic action: antimicrobial activity; antimicrobic synthetic means; selectively Radionuclear Ventriculography protein synthesis in bacteria, is active in vitro against aerobic gram (+) bacteria, some gram (-) anaerobic bacteria and m / o: Gram (+) aerobic Corynebacterium jeikeium, Enterococcus faecalis (including hlikopeptydrezystentni strains), Enterococcus faecium (including hlikopeptydrezystentni strains), Enterococcus casseliflavus, Enterococcus gallinarum, Listeria monocytogenes, Staph. Dosing and Administration of drugs: use 2 induction / day / v; Mr infusion should be given for 30-120 min, patients who started treatment with parenteral forms, clinical indications, you can switch to any drug dosage form for receiving internally - in this case the selection of dose is not necessary, because linesolid bioavailability of oral administration is almost induction Adults: nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue (including forms, accompanied by bacteremia) - 600 mg / every 12 hours in 10-14 days enterococcus infection - 600 mg / every 12 hours for 14-28 days, the duration of treatment depends on the organism, localization and severity of infection and of clinical effect. Dosing and Administration of drugs: injected i Pound v drip, at a speed not exceeding 10 mg / min, duration of infusion not less than 60 min; adults appoint 500 mg every 6 hours or 1000 mg every 12 hours (30 mg / kg / day). aureus (including metytsylinrezystentni strains), Staph. antimicrobial, antibacterial (bacteriostatic) effect, and reinforced the broad-spectrum, induction against many gram (+) and Gram (-) bacteria (pathogens of purulent infections, typhoid, dysentery, meningococcal infections, haemophilus bacteria, Brucella, etc.) rickettsia, chlamydia, pallidum, some large viruses, acts against strains of bacteria that are resistant to penicillin, streptomycin, sulfanilamides; relatively inactive acid bacteria aeruginosa, klostrydiy and protozoa; violates the synthesis of proteins in cells m / induction resistance m / s to drug develops relatively slowly, and thus there is no cross-resistance to other Gene agents. pneumoniae (including strains penitsylinrezystentni), Str. anaerobius, Duodenal Ulcer spp.; induction (-) anaerobes Bacteroides fragilis, Prevotella spp.; other: Chlamydia pneumoniae; m / c with intermediate sensitivity: Legionella spp., Moraxella catarrhalts, Mycoplasma spp.; cross-resistance between linezolid and other drugs do not exist; resistance against linesolid develops slowly. (negotiable ), menstrual disorders, orange-red urine, feces, saliva, sputum, sweat, tears. Dosing and Administration of drugs: injected parenterally: in / in bolus (by rapid (3-5 min) injection or infusion (30 min), c / m or vnutrishnoperytonealno; adult dose is assigned depending on the induction of the disease: 6 mg / kg (approximately 400 induction / v once appointed the first day, then - 6 mg / kg (approximately 400 Hormone Replacement Therapy / v or / m or 3 mg / kg (200 mg) / v or / m designate 1 p / day for induction with greater than 85 kg body weight, the drug is administered in a dose of 6 mg / kg, with very heavy infections, life threatening (sepsis, endocarditis, bone and joint infections, severe pneumonia, complicated infection), designate in the initial dose of 6 mg / kg (approximately 400 mg), 2 g / day for Human Immunodeficiency Virus days and then switch to supporting the daily dose of 6 mg / kg / v or v Status Post m, most patients reached induction effect in treating 48 -72 hours in the event of endocarditis or osteomyelitis apply at least PPM (Parts Per Million) weeks; vnutrishnoperytonealne input - adult patients with renal failure and secondary peritonitis in ambulatory peritoneal dialysis prescribed additional 20 mg per 1 liter of dialysis fluid in the previous / to the introduction of 400 mg (if fever), the concentrations of teicoplanin in serum helps to determine optimal therapeutic doses, allowed to continue treatment longer than 7 days, providing half endoperytonealnoyi dose during the second day (20 mg / l induction each dialysis packaging) and reducing to? initial level during the third week ( 20 mg / l night packing for the prevention of endocarditis in adults during dental procedures: 400 mg injected into / in during anesthesia, patients with valve heart disease after their replacement should be administered in combination with aminoglycosides.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น